NDAINJECTIONINJECTABLE
Approved
Jan 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VESPRIN (triflupromazine hydrochloride) is a typical antipsychotic belonging to the phenothiazine class, administered via injection. Originally approved in 1958, it was used to treat acute psychotic episodes and severe agitation. The drug acts as a dopamine antagonist to manage psychiatric symptoms.
LOE Approaching
Product is in late-stage lifecycle with LOE approaching, suggesting a small, defensive brand team focused on maintaining existing patient base rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VESPRIN offers minimal career growth opportunity given the product's LOE-approaching status and zero linked job openings. Positions on this team are typically maintenance-focused rather than launch or expansion roles, offering stability but limited advancement trajectory.
Product ManagerField Sales Representative
Worked on VESPRIN at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.